164 related articles for article (PubMed ID: 21699746)
1. Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed.
Denton CP; Avouac J; Behrens F; Furst DE; Foeldvari I; Humbert M; Huscher D; Kowal-Bielecka O; Matucci-Cerinic M; Nash P; Opitz CF; Pittrow D; Rubin LJ; Seibold JR; Distler O
Arthritis Res Ther; 2011 Jun; 13(3):114. PubMed ID: 21699746
[TBL] [Abstract][Full Text] [Related]
2. Outcome measures in pulmonary arterial hypertension associated with systemic sclerosis.
Kowal-Bielecka O; Delcroix M; Vonk-Noordegraaf A; Hoeper MM; Naeije R
Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v39-41. PubMed ID: 18784140
[TBL] [Abstract][Full Text] [Related]
3. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
[TBL] [Abstract][Full Text] [Related]
4. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.
Ramjug S; Hussain N; Hurdman J; Billings C; Charalampopoulos A; Elliot CA; Kiely DG; Sabroe I; Rajaram S; Swift AJ; Condliffe R
Chest; 2017 Jul; 152(1):92-102. PubMed ID: 28223154
[TBL] [Abstract][Full Text] [Related]
5. Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).
Sobanski V; Launay D; Hachulla E; Humbert M
Curr Rheumatol Rep; 2016 Feb; 18(2):10. PubMed ID: 26841964
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
[TBL] [Abstract][Full Text] [Related]
7. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.
Clements PJ; Tan M; McLaughlin VV; Oudiz RJ; Tapson VF; Channick RN; Rubin LJ; Langer A;
Ann Rheum Dis; 2012 Feb; 71(2):249-52. PubMed ID: 21998119
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.
Humbert M; Singh M; Furst DE; Khanna D; Seibold JR
Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v33-v37. PubMed ID: 28992168
[TBL] [Abstract][Full Text] [Related]
9. Nailfold capillaroscopic changes in patients with idiopathic pulmonary arterial hypertension and systemic sclerosis-related pulmonary arterial hypertension.
Corrado A; Correale M; Mansueto N; Monaco I; Carriero A; Mele A; Colia R; Di Biase M; Cantatore FP
Microvasc Res; 2017 Nov; 114():46-51. PubMed ID: 28619664
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
[TBL] [Abstract][Full Text] [Related]
11. Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis.
Hofstee HM; Vonk Noordegraaf A; Voskuyl AE; Dijkmans BA; Postmus PE; Smulders YM; Serné EH
Ann Rheum Dis; 2009 Feb; 68(2):191-5. PubMed ID: 18375538
[TBL] [Abstract][Full Text] [Related]
12. Scleroderma pulmonary arterial hypertension: the same as idiopathic pulmonary arterial hypertension?
Khan SL; Mathai SC
Curr Opin Pulm Med; 2023 Sep; 29(5):380-390. PubMed ID: 37461869
[TBL] [Abstract][Full Text] [Related]
13. Bosentan ameliorated exercise-induced pulmonary arterial hypertension complicated with systemic sclerosis.
Yagi S; Akaike M; Iwase T; Kusunose K; Niki T; Yamaguchi K; Koshiba K; Yoshida S; Sumitomo-Ueda Y; Aihara K; Hirata Y; Dagvasumberel M; Taketani Y; Tomita N; Yamada H; Soeki T; Wakatsuki T; Matsumoto T; Sata M
Intern Med; 2010; 49(21):2309-12. PubMed ID: 21048365
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of exercise pulmonary arterial hypertension in scleroderma.
Callejas-Rubio JL; Moreno-Escobar E; de la Fuente PM; Pérez LL; Fernández RR; Sánchez-Cano D; Mora JP; Ortego-Centeno N
J Rheumatol; 2008 Sep; 35(9):1812-6. PubMed ID: 18634147
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.
Mihai C; Antic M; Dobrota R; Bonderman D; Chadha-Boreham H; Coghlan JG; Denton CP; Doelberg M; Grünig E; Khanna D; McLaughlin VV; Müller-Ladner U; Pope JE; Rosenberg DM; Seibold JR; Vonk MC; Distler O
Ann Rheum Dis; 2018 Jan; 77(1):128-132. PubMed ID: 29061853
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management.
Ramirez A; Varga J
Treat Respir Med; 2004; 3(6):339-52. PubMed ID: 15658881
[TBL] [Abstract][Full Text] [Related]
17. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
[TBL] [Abstract][Full Text] [Related]
18. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).
Khanna D; Distler O; Avouac J; Behrens F; Clements PJ; Denton C; Foeldvari I; Giannini E; Huscher D; Kowal-Bielecka O; Lovell D; Matucci-Cerinic M; Mayes M; Merkel PA; Nash P; Opitz CF; Pittrow D; Rubin L; Seibold JR; Steen V; Strand CV; Tugwell PS; Varga J; Zink A; Furst DE; ;
J Rheumatol; 2009 Oct; 36(10):2356-61. PubMed ID: 19820225
[TBL] [Abstract][Full Text] [Related]
19. Systemic sclerosis-associated pulmonary arterial hypertension.
Le Pavec J; Humbert M; Mouthon L; Hassoun PM
Am J Respir Crit Care Med; 2010 Jun; 181(12):1285-93. PubMed ID: 20194816
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review.
Bazan IS; Mensah KA; Rudkovskaia AA; Adonteng-Boateng PK; Herzog EL; Buckley L; Fares WH
Respir Med; 2018 Jan; 134():42-46. PubMed ID: 29413506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
